stoxline Quote Chart Rank Option Currency Glossary
Monopar Therapeutics Inc. (MNPR)
0.855  -0.016 (-1.78%)    06-18 12:04
Open: 0.9
High: 0.912
Volume: 63,952
Pre. Close: 0.8705
Low: 0.83
Market Cap: 15(M)
Technical analysis
2024-06-18 11:51:56 AM
Short term     
Mid term     
Targets 6-month :  1.26 1-year :  1.47
Resists First :  1.08 Second :  1.26
Pivot price 0.79
Supports First :  0.76 Second :  0.56
MAs MA(5) :  0.89 MA(20) :  0.75
MA(100) :  0.68 MA(250) :  0.6
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  59.5 D(3) :  65.5
RSI RSI(14): 58.8
52-week High :  1.73 Low :  0.27
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MNPR ] has closed below upper band by 35.8%. Bollinger Bands are 7.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.93 - 0.94 0.94 - 0.94
Low: 0.84 - 0.85 0.85 - 0.85
Close: 0.85 - 0.86 0.86 - 0.87
Company Description

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Headline News

Mon, 17 Jun 2024
Monopar Therapeutics COO buys shares worth over $32k By -

Fri, 14 Jun 2024
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Down 21.6% in May - Defense World

Tue, 11 Jun 2024
Monopar Therapeutics Enhances Alliance with NorthStar Medical - - TipRanks

Mon, 10 Jun 2024
Monopar Therapeutics Showcases MNPR-101-Zr Progress at SNMMI - - TipRanks

Mon, 10 Jun 2024
Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical ... - GlobeNewswire

Thu, 06 Jun 2024
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 17 (M)
Shares Float 8 (M)
Held by Insiders 52.9 (%)
Held by Institutions 2.2 (%)
Shares Short 80 (K)
Shares Short P.Month 150 (K)
Stock Financials
EPS -0.52
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.43
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -48.4 %
Return on Equity (ttm) -92.7 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -5 (M)
Stock Valuations
PE Ratio -1.66
PEG Ratio 0
Price to Book value 2
Price to Sales 0
Price to Cash Flow -2.08
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android